What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
Florian Lordick mainly investigates Internal medicine, Surgery, Oncology, Gastroenterology and Cancer.
Chemotherapy, Fluorouracil, Colorectal cancer, Adenocarcinoma and Oxaliplatin are the core of his Internal medicine study.
His studies deal with areas such as Chemotherapy regimen and Phases of clinical research as well as Fluorouracil.
His Surgery research is multidisciplinary, incorporating elements of Cetuximab and Clinical trial.
His work deals with themes such as Neoadjuvant therapy, Carcinoma, Radiation therapy and Panitumumab, which intersect with Oncology.
His study in the field of Trastuzumab is also linked to topics like Audit.
His most cited work include:
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial (4132 citations)
- Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer (761 citations)
- Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial (727 citations)
What are the main themes of his work throughout his whole career to date?
Florian Lordick mainly focuses on Internal medicine, Cancer, Oncology, Chemotherapy and Surgery.
His Internal medicine study frequently links to other fields, such as Gastroenterology.
His Cancer study combines topics from a wide range of disciplines, such as Cancer research, Perioperative and Pathology.
In Oncology, Florian Lordick works on issues like Neoadjuvant therapy, which are connected to Survival rate.
His Chemotherapy research includes elements of Regimen and Surgical oncology.
His Randomized controlled trial and Clinical endpoint study, which is part of a larger body of work in Surgery, is frequently linked to In patient, bridging the gap between disciplines.
He most often published in these fields:
- Internal medicine (57.01%)
- Cancer (39.82%)
- Oncology (37.78%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (57.01%)
- Cancer (39.82%)
- Oncology (37.78%)
In recent papers he was focusing on the following fields of study:
His main research concerns Internal medicine, Cancer, Oncology, Chemotherapy and In patient.
Florian Lordick regularly ties together related areas like Gastroenterology in his Internal medicine studies.
His study in Gastroenterology is interdisciplinary in nature, drawing from both Increased risk, Placebo, Capecitabine and Hazard ratio.
Florian Lordick combines subjects such as Young adult, Quality of life, Stage and Anxiety with his study of Cancer.
Florian Lordick has included themes like Pembrolizumab, Precision medicine, Clinical trial, Paclitaxel and Adenocarcinoma in his Oncology study.
His Chemoradiotherapy study in the realm of Chemotherapy interacts with subjects such as Clinical decision making.
Between 2019 and 2021, his most popular works were:
- Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. (46 citations)
- Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer (34 citations)
- ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer (26 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Surgery
His primary areas of study are Internal medicine, Cancer, Chemotherapy, Oncology and Gastroenterology.
His work carried out in the field of Cancer brings together such families of science as Young adult, Helicobacter pylori, Quality of life and Cohort.
His Chemotherapy research integrates issues from Poor prognosis, Adjuvant and Radiation therapy.
His work in the fields of Ramucirumab overlaps with other areas such as Model selection.
Florian Lordick interconnects Taxane, Trastuzumab and Adenocarcinoma in the investigation of issues within Ramucirumab.
As a part of the same scientific family, he mostly works in the field of Gastroenterology, focusing on Hazard ratio and, on occasion, Loading dose, Oxaliplatin, Capecitabine, Epirubicin and Progressive disease.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
